Oncology Intelligence
Focused analysis of global oncology pipelines, immunotherapy breakthroughs, regulatory acceleration pathways and competitive strategy across major pharmaceutical markets.
Oncology remains the largest therapeutic category globally.
Immuno-oncology, ADCs, targeted therapies and combination regimens are redefining competitive positioning.
Counterfeit Cancer Drugs Seized Worldwide as WHO Issues Medical Product Alert
May 28, 2026
WHO issues urgent warnings after counterfeit oncology drugs including Imfinzi and Ibrance were discovered across multiple countries, exposing major risks to patient safety and global pharmaceutical supply chains.
Global Counterfeit Drugs and CAR-T Scams: How Gray Market Channels Threaten Cancer Patient Safety
May 28, 2026
How counterfeit drugs, gray market channels, and unverified CAR-T services are creating growing risks for global cancer patients and why supply chain transparency matters more than ever.
A New Direction in the Treatment of RAS-Mutant Cancers: Insights from Clinical Studies of daraxonrasib
May 26, 2026
Next-generation pan-RAS inhibitor daraxonrasib is showing promising clinical signals in RAS-mutant cancers, including pancreatic cancer and NSCLC, marking a new stage in precision oncology.
April 2026 Breakthroughs in Cancer Treatment: 26 New Projects Launched, Advances in Immunotherapy and Precision Targeting
May 22, 2026
From Laboratory to Clinical Practice: The Translational Medicine Journey of Nanomedicine in Targeted Cancer Therapy
May 22, 2026
Spatial Biology: From ‘Average Tumor’ to ‘Cell-Level Precision Therapy’
May 21, 2026
Spatial biology is reshaping cancer precision medicine by mapping the tumor microenvironment at cellular resolution and enabling personalized immunotherapy strategies.
7-Minute Immunotherapy Infusion! Atezolizumab Subcutaneous Injection Approved in China
May 20, 2026
Atezolizumab subcutaneous injection has been approved in China, allowing PD-L1 immunotherapy administration in about 7 minutes and improving convenience for cancer patients.
Dual Oral Therapy, Chemotherapy-Free! EGFR-Mutant Lung Cancer Treatment May Enter a New Era
May 20, 2026
ABSK043 combined with Furmonertinib may open a new chemotherapy-free era for EGFR-mutant lung cancer through a fully oral targeted therapy and immunotherapy combination strategy.
China vs Western Cancer Treatment: What Are the Differences?
May 18, 2026
Explore the key differences between cancer treatment in China and Western countries, including CAR-T therapy, treatment costs, waiting times, precision medicine, and cross-border healthcare services for international patients.
Y-90 (Yttrium-90) Treatment in China: A New Interventional Radiotherapy Option for International Liver Cancer Patients
May 18, 2026
Learn how Y-90 (Yttrium-90) radioembolization treatment in China is attracting international liver cancer patients through advanced interventional oncology, multidisciplinary care, and cross-border medical services.
Why Are More International Patients Choosing Medical Treatment in China?
May 14, 2026
Explore why China is becoming a major destination for international patients seeking oncology treatment, precision medicine, JCI-accredited hospitals, and cross-border healthcare services.
Is CAR-T Therapy in China Open to International Patients?
May 13, 2026
From Precision Medicine to CAR-T: Why Are China’s JCI Cancer Hospitals Attracting Increasing Global Attention?
May 13, 2026
Breast Cancer Screening Guide: What Should Women of Different Ages Do?
May 09, 2026
A practical breast cancer screening guide for women of different ages, including mammography, ultrasound, high-risk screening, and the importance of early detection.
Is Helicobacter pylori Infection Guaranteed to Cause Stomach Cancer? Many People Have Misunderstood It
May 09, 2026
Learn the relationship between Helicobacter pylori infection and stomach cancer, common symptoms, testing methods, risk factors, and how to protect stomach health.
Complete Guide for Early Cancer Screening｜A Review of Screening Methods for 6 Common Cancers
May 07, 2026
A comprehensive guide to early cancer screening methods, high-risk populations, and recommended screening intervals for six common cancers.
cadonilimab in pancreatic cancer: immunotherapy breakthrough at aacr 2026
May 06, 2026
Proposed Breakthrough Therapy Designation: Keymed’s CM336 Poised to Reshape the Treatment Landscape of AL Amyloidosis
May 06, 2026
BCMA-Targeted ADC Therapy: A New Direction for Precision Treatment of Multiple Myeloma
April 30, 2026
HLX43: A Next-Generation PD-L1-Targeted ADC Breaking Traditional Limitations in Cancer Therapy
April 30, 2026
HLX43, a next-generation PD-L1-targeted ADC, introduces a novel mechanism independent of T cells and microtubules, offering new options for resistant and low PD-L1 tumors.